These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 33922418)
1. Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Park GT; Yoon JW; Yoo SB; Song YC; Song P; Kim HK; Han J; Bae SJ; Ha KT; Mishchenko NP; Fedoreyev SA; Stonik VA; Kim MB; Kim JH Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33922418 [TBL] [Abstract][Full Text] [Related]
2. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH Front Immunol; 2019; 10():2095. PubMed ID: 31552041 [TBL] [Abstract][Full Text] [Related]
3. Withaferin A attenuates bleomycin-induced scleroderma by targeting FoxO3a and NF-κβ signaling: Connecting fibrosis and inflammation. Bale S; Pulivendala G; Godugu C Biofactors; 2018 Nov; 44(6):507-517. PubMed ID: 30367690 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491 [TBL] [Abstract][Full Text] [Related]
5. Scleroderma-like Impairment in the Network of Telocytes/CD34 Rosa I; Romano E; Fioretto BS; Guasti D; Ibba-Manneschi L; Matucci-Cerinic M; Manetti M Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830288 [TBL] [Abstract][Full Text] [Related]
6. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. Ohashi T; Yamamoto T Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255 [TBL] [Abstract][Full Text] [Related]
7. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Zhang Z; Wu Y; Wu B; Qi Q; Li H; Lu H; Fan C; Feng C; Zuo J; Niu L; Tang W Arthritis Res Ther; 2019 Dec; 21(1):290. PubMed ID: 31842999 [TBL] [Abstract][Full Text] [Related]
8. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756 [TBL] [Abstract][Full Text] [Related]
9. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities. Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081 [TBL] [Abstract][Full Text] [Related]
10. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma. Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557 [TBL] [Abstract][Full Text] [Related]
11. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. Yang L; Serada S; Fujimoto M; Terao M; Kotobuki Y; Kitaba S; Matsui S; Kudo A; Naka T; Murota H; Katayama I PLoS One; 2012; 7(7):e41994. PubMed ID: 22911870 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630 [TBL] [Abstract][Full Text] [Related]
13. Immunophenotypical analysis of myofibroblasts and mesenchymal cells in the bleomycin-induced rat scleroderma, with particular reference to their origin. Juniantito V; Izawa T; Yuasa T; Ichikawa C; Tanaka M; Kuwamura M; Yamate J Exp Toxicol Pathol; 2013 Jul; 65(5):567-77. PubMed ID: 22749686 [TBL] [Abstract][Full Text] [Related]